BELANTAMAB MAFODOTIN

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Mon Mar 31 22:04:36 GMT 2025` Edited by `admin` on `Mon Mar 31 22:04:36 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type	IGG1
Sequence Origin	HUMANIZED MURINE
Sequence Type	COMPLETE
Record UNII	DB1041CXDG
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

BELANTAMAB MAFODOTIN

Official Name

English

belantamab mafodotin [INN]

Preferred Name

English

GSK2857916

Code

English

BELANTAMAB MAFODOTIN [MI]

Common Name

English

BELANTAMAB MAFODOTIN [USAN]

Common Name

English

GSK-2857916

Code

English

Belantamab mafodotin [WHO-DD]

Common Name

English

BELANTAMAB MAFODOTIN [JAN]

Common Name

English

IMMUNOGLOBULIN G1, ANTI-(TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY PROTEIN TNFRSF17),(HUMANIZED MONOCLONAL GSK2857914 .GAMMA.1-CHAIN), DISULFIDE WITH HUMANIZED MONOCLONAL GSK2857914 .KAPPA.-CHAIN, DIMER, TETRATHIOETHER WITH N-(6-(3-MERCAPTO-2,5-DIOXO-1-

Systematic Name

English

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 17 (B-CELL MATURATION PROTEIN, ANTIGEN CD269))HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO AURISTATIN F.GAMMA.1 HEAVY CHAIN (1-451) (HUMANIZED VH (HOMO SAPIENS I

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

590517

Created by admin on Mon Mar 31 22:04:36 GMT 2025 , Edited by admin on Mon Mar 31 22:04:36 GMT 2025

Code System Code Type Description

NCI_THESAURUS

C114299

Created by admin on Mon Mar 31 22:04:36 GMT 2025 , Edited by admin on Mon Mar 31 22:04:36 GMT 2025

PRIMARY

USAN

GH-35

Created by admin on Mon Mar 31 22:04:36 GMT 2025 , Edited by admin on Mon Mar 31 22:04:36 GMT 2025

PRIMARY

CAS

2050232-20-5

Created by admin on Mon Mar 31 22:04:36 GMT 2025 , Edited by admin on Mon Mar 31 22:04:36 GMT 2025

PRIMARY

WIKIPEDIA

Belantamab mafodotin

Created by admin on Mon Mar 31 22:04:36 GMT 2025 , Edited by admin on Mon Mar 31 22:04:36 GMT 2025

PRIMARY

INN

10754

Created by admin on Mon Mar 31 22:04:36 GMT 2025 , Edited by admin on Mon Mar 31 22:04:36 GMT 2025

PRIMARY

FDA UNII

DB1041CXDG

Created by admin on Mon Mar 31 22:04:36 GMT 2025 , Edited by admin on Mon Mar 31 22:04:36 GMT 2025

PRIMARY

LACTMED

Belantamab Mafodotin

Created by admin on Mon Mar 31 22:04:36 GMT 2025 , Edited by admin on Mon Mar 31 22:04:36 GMT 2025

PRIMARY

RXCUI

2387834

Created by admin on Mon Mar 31 22:04:36 GMT 2025 , Edited by admin on Mon Mar 31 22:04:36 GMT 2025

PRIMARY

MERCK INDEX

m12230

Created by admin on Mon Mar 31 22:04:36 GMT 2025 , Edited by admin on Mon Mar 31 22:04:36 GMT 2025

PRIMARY

CAS

1629760-04-8

Created by admin on Mon Mar 31 22:04:36 GMT 2025 , Edited by admin on Mon Mar 31 22:04:36 GMT 2025

NO STRUCTURE GIVEN

DAILYMED

DB1041CXDG

Created by admin on Mon Mar 31 22:04:36 GMT 2025 , Edited by admin on Mon Mar 31 22:04:36 GMT 2025

PRIMARY

SMS_ID

100000181695

Created by admin on Mon Mar 31 22:04:36 GMT 2025 , Edited by admin on Mon Mar 31 22:04:36 GMT 2025

PRIMARY

From	To
1_22	1_96
2_22	2_96
2_148	2_204
2_224	4_214
2_265	2_325
1_148	1_204
2_371	2_429
3_23	3_88
3_134	3_194
4_23	4_88
4_134	4_194
1_224	3_214
1_230	2_230
1_233	2_233
1_265	1_325
1_371	1_429

Glycosylation Type

MAMMALIAN, AFUCOSYLATED

Glycosylation Link Type	Site
N	1_301
N	2_301

Related Record Type Details


					7M3UL8MR2Y

CONJUGATE COMPONENT->CONJUGATE

Amount:


					O19V2N6W9T

MAFODOTIN

CONJUGATE COMPONENT->CONJUGATE

Amount:


					PK6VHJAIBD

TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 17

TARGET->CONJUGATED TOXIN

Amount:


					1Z1AI9IW5L

MONOMETHYL AURISTATIN F

TOXIN -> CONJUGATE

Amount:

BELANTAMAB MAFODOTIN-BLMF

SUB_CONCEPT->SUBSTANCE

Amount:


					NN8BA411GP

LOW AFFINITY IMMUNOGLOBULIN GAMMA FC REGION RECEPTOR III-A

BINDER->LIGAND

Amount:

Related Record Type Details


					DB1041CXDG

BELANTAMAB MAFODOTIN

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_224] [1_230] [1_233] [2_224] [2_230] [2_233] [3_214] [4_214]		CYSTEINE	Amount:	CYSTEINYL-MAFODOTIN	B4S8ET206U
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS			PIDOLIC ACID	SZB83O1W42

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL